AKL’s data on APPA’s Phase IIa Human Clinical Trial, ‘The Efficacy & Safety of APPA in Symptomatic Knee Osteoarthritis’, was presented as a scientific abstract and as a poster at the congress for European Alliance of Associations for Rheumatology (EULAR) 2022.
The APPA phase IIa trial was designed to assess the efficacy of APPA in subjects mild, moderate and more severe osteoarthritis, and, in predefined subgroups, to identify those who would benefit the most. this trial successfully identified subjects with more severe disease benefited with a statistically significant improvement in pain vs placebo although the primary endpoint (WOMAC pain score) for all patients was not achieved. In addition, a subgroup with greater pain and with OA in both knees also benefitted from a significant improvement with APPA vs placebo.
The data was also presented as a poster at the 2022 OARSI World Congress On Osteoarthritis (Osteoarthritis Research Society International). OARSI is a key congress focused exclusively on osteoarthritis and ALK was proud to sponsor of this year’s ‘Rising Star Awards’ at the congress.